4 January 2016
Use of Anticholinergic Drugs Does Not Increase Risk for Dementia in Parkinson’s Disease Patients
Recent evidence has shown a greater risk of dementia, in particular Alzheimer’s disease (AD), in individuals using anticholinergic medications regularly. These drugs are widely used by older adults to treat bladder dysfunction, mood, and pain, and many of them are available without prescription. Since these drugs are often used to treat both motor symptoms and non-motor symptoms in patients with Parkinson’s Disease (PD), there is concern for increased risk of dementia. Contrary to expectations, a study in the current issue of the Journal of Parkinson’s Disease determined that the cognitive performance of PD patients taking anticholinergic medications did not differ from those who did not.
10 November 2015
Gaucher Disease May Protect Against Parkinson’s Disease-Related Color Visual Impairment
Parkinson’s Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the β-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD). Patients with both PD and GD tend to experience earlier onset of PD and more serious cognitive changes than PD patients without the mutations. A new study published in the Journal of Parkinson’s Disease suggests that GD or the presence of GBA mutations may actually shield patients from deficiency in visual color discrimination, which is a hallmark of PD.
10 November 2015
Does Alcohol Consumption Affect the Risk for Parkinson’s Disease?
For many years, researchers have been investigating whether there are any associations between Parkinson’s disease (PD) and lifestyle choices such as smoking and coffee and alcohol consumption. In a review published in the Journal of Parkinson’s Disease, the literature concerning alcohol consumption presents conflicting information.
21 October 2015
Jon Palfreman's new book: Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease
The Journal of Parkinson’s Disease is proud to announce the publication of Media Editor Jon Palfreman’s newest book: “Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease”, a long-overdue, riveting detective story of the race to stop or reverse neurodegenerative conditions like Parkinson's disease, and a passionate, insightful account into the lives of those affected.
24 June 2015
New Study Calls for Partnering of Parkinson’s Disease Research Community with Patient Groups to Improve Effectiveness of Clinical Trials
Despite an urgent need for new medications, clinical trials in Parkinson’s disease (PD) have a relatively low rate of success. The reasons for this are complex, prompting a group of investigators from PD advocacy groups to conduct a survey of the principle stakeholders, PD scientists, patients, and caregivers, to determine some of the underlying barriers. Their results are published in the Journal of Parkinson’s Disease.
24 June 2015
What Is the Role of the Gut Microbiome in Developing Parkinson’s Disease?
In recent years, an important Parkinson’s disease (PD) research focus has been on gut-related pathology, pathophysiology, and symptoms. Gastrointestinal dysfunction, in particular constipation, affects up to 80% of PD patients and idiopathic constipation is one of the strongest risk-factors for PD. Lifestyle factors such as smoking and coffee consumption, as well as blood urate levels, have been associated with a decreased PD risk.
26 February 2015
Levodopa-Carbidopa Intestinal Gel May Prove More Effective for Long-Term Treatment of Parkinson’s Disease than Standard Levodopa
Although levodopa remains the “gold standard” to effectively control motor deficits in the treatment of early stage Parkinson’s disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson’s disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in “On/Off” states. By nine years of treatment, about 90% will suffer these effects.
25 February 2015
Parkinson’s Disease Patients Have Reduced Visual Contrast Acuity
Patients with Parkinson’s disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson’s Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients’ vision was deficient at far distances.
18 November 2014
Simple Clinical Tests Help Differentiate Parkinson’s Disease from Atypical Parkinsonism
Two simple tests conducted during the neurological exam can help clinicians differentiate between early-stage Parkinson’s disease (PD) and atypical parkinsonism. By asking patients to perform a tandem gait test and inquiring whether they are still able to ride a bicycle, clinicians can ascertain whether medio-lateral balance is impaired, a defining characteristic of atypical parkinsonism. These findings are published in the Journal of Parkinson’s Disease.
11 September 2014
Few Mild-to-Moderate PD Patients Suffer from Malnutrition, Yet Almost One Third Are at Risk
Patients with Parkinson’s disease (PD) can experience difficulties with food preparation and ingestion, which could contribute to poor nutrition and place them at risk for malnourishment. Published studies have also suggested that PD is associated with low weight, however, few studies included control groups. A report published in the Journal of Parkinson’s Disease counters this conclusion in patients with mild-to-moderate PD, finding that the incidence or risk of malnutrition is no different for patients with mild-to-moderate PD compared to healthy controls.
Pages
